{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:01:13Z","timestamp":1698714073868},"reference-count":132,"publisher":"Wiley","issue":"s72","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1111\/j.1600-0609.2010.01461.x","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T08:56:18Z","timestamp":1276678578000},"page":"1-28","source":"Crossref","is-referenced-by-count":28,"title":["Meeting the Unmet Needs in Anticoagulant Therapy"],"prefix":"10.1111","volume":"85","member":"311","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05249-1"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012385"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107193450302"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903253401201"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595140"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090041008"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.2.527"},{"key":"e_1_2_4_9_2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials","volume":"154","author":"Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study","year":"1994","journal-title":"Arch Intern Med"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2009.03.080218"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl146"},{"key":"e_1_2_4_13_2","first-page":"e257","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"11","author":"Fuster V","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.091"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.06.077"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-5-200909010-00003"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb05967.x"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.3.244"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-07-0434"},{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0656"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.14.1525"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.11.1337"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351002"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)01453-5"},{"key":"e_1_2_13_7_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0038-1655901","article-title":"Prolonged thromboprophylaxis following total hip replacement surgery \u2013 results of a double\u2010blind, prospective, randomised, placebo\u2010controlled study with dalteparin (Fragmin)","volume":"77","author":"Dahl OE","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2208"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-11-200006060-00002"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200103000-00004"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-10-200111200-00006"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05249-1"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-200903000-00007"},{"key":"e_1_2_13_14_2","unstructured":"Venous thromboembolism: the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing orthopaedic surgery and other high\u2010risk surgical procedures. NICE guideline. Available at:http:\/\/www.nice.org.uk\/nicemedia\/pdf\/VTEConsultationNICEVersion0906.pdf. Accessed February 12 2010."},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/014107688908200407"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-4-200702200-00007"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411103"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000138928.83266.24"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38733.466748.7C"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-7732-5"},{"issue":"2","key":"e_1_2_13_26_2","first-page":"O\u2010S\u2010001","article-title":"Extended\u2010duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the exclaim study","volume":"5","author":"Hull RD","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_13_27_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1862.1862","article-title":"The effects of the degree of mobility reduction and prespecified risk factors on venous thromboembolism rates in acutely ill medical patients in the EXCLAIM study","volume":"110","author":"Yusen RD","year":"2007","journal-title":"Blood"},{"key":"e_1_2_13_28_2","unstructured":"Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN). Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00571649?term=rivaroxaban&rank=15. Accessed February 11 2010."},{"key":"e_1_2_13_29_2","unstructured":"LassenRL GallusAS PineoGF et\u00a0al.; ADVANCE\u20131 Investigators. Randomized double\u2010blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE\u20131 trial [abstract]. 50th American Society of Hematology Annual Meeting and Exposition. December 6\u20139 2008. San Francisco California. Abstract 31. Available at:http:\/\/ash.confex.com\/ash\/2008\/webprogram\/Paper4437.html. Accessed June 18 2009."},{"key":"e_1_2_13_30_2","unstructured":"Study of Apixaban for the Prevention of Thrombosis\u2010related Events in Patients With Acute Medical Illness (ADOPT). Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00457002?term=apixaban&rank=4. Accessed February 11 2010."},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.89B6.18844"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2993"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0667"},{"key":"e_1_2_29_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.19.1.75"},{"key":"e_1_2_29_3_2","first-page":"163","article-title":"Heparin and thrombosis of veins following injury","volume":"2","author":"Murray D","year":"1937","journal-title":"Surgery"},{"key":"e_1_2_29_4_2","first-page":"407","article-title":"Preliminary report on post\u2010operative treatment with heparin as a preventive of thrombosis","volume":"79","author":"Crafoord C","year":"1937","journal-title":"Act Chir Scand"},{"key":"e_1_2_29_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(60)92299-6"},{"key":"e_1_2_29_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0658"},{"key":"e_1_2_29_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-4-279"},{"key":"e_1_2_29_8_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex\u2010vivo and in\u2010vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin","volume":"71","author":"Young E","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_29_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242206"},{"key":"e_1_2_29_10_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0677"},{"key":"e_1_2_29_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0658"},{"key":"e_1_2_29_12_2","first-page":"CD001100","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism","author":"Van Dongen CJ","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_29_13_2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1055\/s-0037-1616520","article-title":"Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta\u2010analysis","volume":"86","author":"Couturaud F","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_29_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.12.1769"},{"key":"e_1_2_29_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.20.3160"},{"issue":"6","key":"e_1_2_29_16_2","first-page":"175","article-title":"Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program","volume":"18","author":"Groce JB","year":"1998","journal-title":"Pharmacotherapy"},{"key":"e_1_2_29_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.19.2298"},{"key":"e_1_2_29_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.108"},{"key":"e_1_2_29_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-34309"},{"key":"e_1_2_29_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-11-200406010-00007"},{"key":"e_1_2_29_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035451"},{"key":"e_1_2_29_22_2","article-title":"Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra\u00ae): The MATISSE Trials [ASH Annual Meeting Abstracts]","volume":"104","author":"B\u00fcller HR","year":"2004","journal-title":"Blood"},{"key":"e_1_2_29_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064247"},{"key":"e_1_2_29_24_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_29_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0652"},{"key":"e_1_2_29_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005274550"},{"key":"e_1_2_29_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_29_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019083"},{"key":"e_1_2_29_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_29_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286904"},{"key":"e_1_2_29_31_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025569"},{"issue":"1","key":"e_1_2_29_32_2","article-title":"Co\u2010administration of rivaroxaban \u2013 a novel, oral, direct Factor Xa inhibitor \u2013 and clopidogrel in healthy subjects","volume":"28","author":"Kubitza D","year":"2007","journal-title":"Eur Heart J"},{"key":"e_1_2_29_33_2","article-title":"No interaction between the novel, oral direct Factor Xa inhibitor BAY 59\u20107939 and digoxin","volume":"46","author":"Kubitza D","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_29_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02776.x"},{"key":"e_1_2_29_35_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.905.905","article-title":"The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor","volume":"108","author":"Kubitza D","year":"2006","journal-title":"Blood"},{"key":"e_1_2_29_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296058"},{"key":"e_1_2_29_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03298.x"},{"key":"e_1_2_29_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_29_39_2","unstructured":"Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep\u2010vein thrombosis without symptomatic pulmonary embolism: Einstein\u2010DVT Evaluation. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00440193. Accessed January 26 2010."},{"key":"e_1_2_29_40_2","unstructured":"Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep\u2010vein thrombosis: Einstein\u2013PE Evaluation. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00439777. Accessed January 26 2010."},{"key":"e_1_2_29_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.6.706"},{"key":"e_1_2_29_42_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-11-200712040-00007"},{"key":"e_1_2_29_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)01109-9"},{"key":"e_1_2_29_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.8.853"},{"key":"e_1_2_29_45_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-11-200312020-00007"},{"key":"e_1_2_29_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.3.229"},{"key":"e_1_2_29_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067703"},{"key":"e_1_2_29_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03746.x"},{"key":"e_1_2_29_49_2","unstructured":"B\u00fcllerHR DestorsJM GallusAS PrinsMH RaskobGE. Idrabiotaparinux a biotinylated long\u2010acting anticoagulant in the treatment of deep venous thrombosis (EQUINOX Study): safety efficacy and reversibility by avidin. Available athttp:\/\/ash.confex.com\/ash\/2008\/webprogram\/Paper4671.html. Accessed January 26 2010."},{"key":"e_1_2_29_50_2","unstructured":"Kongressbericht \u2013 ESC\u2010Kongress August 2009 Barcelona. Zeitschrift f\u00fcr Gef\u00e4\u00dfmedizin. 2009;6(4) 32. Available athttp:\/\/www.kup.at\/kup\/pdf\/8524.pdf. Accessed January 26 2010."},{"key":"e_1_2_41_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0685"},{"key":"e_1_2_41_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.013"},{"key":"e_1_2_41_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.55"},{"key":"e_1_2_41_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb05967.x"},{"key":"e_1_2_41_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.001"},{"key":"e_1_2_41_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_41_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.1.26"},{"key":"e_1_2_41_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-200508000-00003"},{"key":"e_1_2_41_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.1.61"},{"key":"e_1_2_41_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-4-200508160-00005"},{"key":"e_1_2_41_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09409-6"},{"key":"e_1_2_41_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01118-9"},{"key":"e_1_2_41_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14287-0"},{"key":"e_1_2_41_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.259"},{"key":"e_1_2_41_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.832139"},{"key":"e_1_2_41_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_2_41_18_2","unstructured":"Phase III Acute Coronary Syndrome (APPRAISE\u20132).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00831441?term=apixaban&rank=16. Accessed October 14 2009."},{"key":"e_1_2_41_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"e_1_2_41_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.2.527"},{"key":"e_1_2_41_21_2","first-page":"1449","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [erratum in Arch Intern Med 1994;154:2254]","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"e_1_2_41_22_2","first-page":"1903","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"36","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet"},{"key":"e_1_2_41_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595140"},{"key":"e_1_2_41_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-7-199304010-00005"},{"key":"e_1_2_41_25_2","doi-asserted-by":"publisher","DOI":"10.4065\/70.8.725"},{"key":"e_1_2_41_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-11-199606010-00004"},{"key":"e_1_2_41_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.3.229"},{"key":"e_1_2_41_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0233-1"},{"key":"e_1_2_41_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.7.967"},{"key":"e_1_2_41_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809329"},{"key":"e_1_2_41_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_41_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.06.004"},{"key":"e_1_2_41_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl488"},{"key":"e_1_2_41_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm186"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01461.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01461.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T20:10:53Z","timestamp":1694463053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01461.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":132,"journal-issue":{"issue":"s72","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01461.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01461.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}